Published in J Thorac Cardiovasc Surg on June 01, 1990
Inappropriate dosing of cefuroxime in cardiac surgery. J Thorac Cardiovasc Surg (1992) 0.75
Cefuroxime prophylaxis in cardiovascular surgery: clinical, microbiological, and ecological impact. Tex Heart Inst J (1992) 0.75
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA (1995) 9.54
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med (1988) 6.78
Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis (1974) 6.38
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1994) 6.11
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 5.46
Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med (1992) 5.28
Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA (1996) 4.80
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis (1995) 4.36
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med (1989) 4.23
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Enhanced isolation of Mycoplasma pneumoniae from throat washings with a newly-modified culture medium. J Infect Dis (1979) 4.15
Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother (2000) 4.12
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis (1999) 3.92
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol (1994) 3.77
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med (1995) 3.75
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother (1994) 3.59
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis (1998) 3.58
Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med (1996) 3.53
Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis (1986) 3.51
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol (2002) 3.30
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med (1991) 3.24
Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Ann Intern Med (1980) 3.20
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 3.13
Association of slime with pathogenicity of coagulase-negative staphylococci causing nosocomial septicemia. J Clin Microbiol (1985) 3.13
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med (1989) 2.97
Clinical laboratory comparison of a slide blood culture system with a conventional broth system. J Clin Microbiol (1982) 2.95
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis (1998) 2.94
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 2.89
Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med (1995) 2.86
Transmission of rhinovirus colds by self-inoculation. N Engl J Med (1973) 2.80
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.77
Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol (1990) 2.72
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis (1997) 2.70
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis (1998) 2.67
Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (1994) 2.67
Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis (1997) 2.67
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis (1999) 2.63
A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei. N Engl J Med (1994) 2.61
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis (1999) 2.61
Comparison of the Septi-Chek AFB and BACTEC systems and conventional culture for recovery of mycobacteria. J Clin Microbiol (1993) 2.58
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis (1999) 2.57
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. Clin Infect Dis (1996) 2.52
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 2.50
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med (1995) 2.48
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother (1998) 2.43
Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med (1991) 2.33
Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother (2002) 2.33
The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 2.32
Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol (2002) 2.29
Long-term survival and function after suspected gram-negative sepsis. JAMA (1995) 2.27
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother (1991) 2.26
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis (2000) 2.22
Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol (1994) 2.22
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest (1978) 2.19
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother (1998) 2.18
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA (1993) 2.18
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Use of extracorporeal life support in patients with congenital heart disease. Crit Care Med (1992) 2.13
Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain. J Infect Dis (1981) 2.12
Handwashing compliance by health care workers: The impact of introducing an accessible, alcohol-based hand antiseptic. Arch Intern Med (2000) 2.10
Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA (1991) 2.07
Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med (1993) 2.05
Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med (1998) 2.04
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis (1998) 2.04
Smallpox vaccination for investigators using vaccinia recombinants. Lancet (1989) 2.00